Literature DB >> 25921512

Characterization of MDR and XDR Streptococcus pneumoniae in Canada, 2007-13.

Alyssa R Golden1, Margot Rosenthal2, Ben Fultz2, Kimberly A Nichol3, Heather J Adam4, Matthew W Gilmour5, Melanie R Baxter2, Daryl J Hoban4, James A Karlowsky4, George G Zhanel2.   

Abstract

OBJECTIVES: The goal of this study was to characterize Streptococcus pneumoniae demonstrating MDR (resistant to three or more antimicrobial classes) or XDR (resistant to five or more classes) phenotypes, collected from Canada during the CANWARD 2007-13 study.
METHODS: From 2007 to 2013 inclusive, S. pneumoniae isolates were collected as a part of the CANWARD surveillance study. MDR and XDR isolates were subjected to PFGE, MLST, molecular detection of pneumococcal pili and macrolide resistance determinants mef(A/E) and erm(B), sequencing of PBPs 1A, 2B and 2X and comparison with Pneumococcal Molecular Epidemiology Network (PMEN) clones.
RESULTS: Of 2129 S. pneumoniae isolates collected during the CANWARD 2007-13 study, 61 (2.9%) were found to be MDR. Of these MDR isolates, 43 (70.5%) were XDR. The most common serotypes for both MDR and XDR S. pneumoniae were 19A and 19F. Twenty-nine of 61 isolates (48%) demonstrated resistance to clarithromycin, clindamycin, doxycycline, penicillin and trimethoprim/sulfamethoxazole. All isolates possessed at least one macrolide resistance determinant and mutations in PBPs 1A, 2B and 2X. The most common clone was piliated, XDR ST320, an internationally circulating double-locus variant of Taiwan(19F)-14 (ST236).
CONCLUSIONS: Though the rate of MDR S. pneumoniae has remained relatively stable since 2007, XDR strains have emerged in Canada. These strains are virulent, possess resistance determinants and are related to international clones.
© The Author 2015. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  S. pneumoniae; extensively drug resistant; molecular characterization; multidrug resistant; resistance mechanisms

Mesh:

Substances:

Year:  2015        PMID: 25921512     DOI: 10.1093/jac/dkv107

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  15 in total

1.  Antibacterial Activity of Lefamulin against Pathogens Most Commonly Causing Community-Acquired Bacterial Pneumonia: SENTRY Antimicrobial Surveillance Program (2015-2016).

Authors:  Susanne Paukner; Steven P Gelone; S J Ryan Arends; Robert K Flamm; Helio S Sader
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

2.  In vitro activity of tedizolid against Staphylococcus aureus and Streptococcus pneumoniae collected in 2013 and 2014 from sites in Latin American countries, Australia, New Zealand, and China.

Authors:  D J Biedenbach; S K Bouchillon; B Johnson; J Alder; D F Sahm
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-09-27       Impact factor: 3.267

3.  In Vitro Activities of Ceftaroline and Comparators against Streptococcus pneumoniae Isolates from U.S. Hospitals: Results from Seven Years of the AWARE Surveillance Program (2010 to 2016).

Authors:  Michael A Pfaller; Rodrigo E Mendes; Leonard R Duncan; Robert K Flamm; Helio S Sader
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

4.  Dalbavancin Activity When Tested against Streptococcus pneumoniae Isolated in Medical Centers on Six Continents (2011 to 2014).

Authors:  Ronald N Jones; Jason E Schuchert; Rodrigo E Mendes
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

5.  Antimicrobial resistance, penicillin-binding protein sequences, and pilus islet carriage in relation to clonal evolution of Streptococcus pneumoniae serotype 19A in Russia, 2002-2013.

Authors:  N Mayanskiy; T Savinova; N Alyabieva; O Ponomarenko; E Brzhozovskaya; A Lazareva; L Katosova; R Kozlov
Journal:  Epidemiol Infect       Date:  2017-03-20       Impact factor: 4.434

6.  The biofilm inhibitor Carolacton inhibits planktonic growth of virulent pneumococci via a conserved target.

Authors:  Jannik Donner; Michael Reck; Simone Bergmann; Andreas Kirschning; Rolf Müller; Irene Wagner-Döbler
Journal:  Sci Rep       Date:  2016-07-11       Impact factor: 4.379

7.  Serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae isolates from a Phase III community-acquired bacterial pneumonia (CABP) trial.

Authors:  S P McCurdy; A J Sheets; S K Cammarata; J E Vidal
Journal:  JAC Antimicrob Resist       Date:  2021-05-04

8.  Serotype Distribution and Antimicrobial Resistance of Streptococcus pneumoniae Isolates Causing Invasive and Noninvasive Pneumococcal Diseases in Korea from 2008 to 2014.

Authors:  Si Hyun Kim; Il Kwon Bae; Dongchul Park; Kyungmin Lee; Na Young Kim; Sae Am Song; Hye Ran Kim; Ga Won Jeon; Sang-Hwa Urm; Jeong Hwan Shin
Journal:  Biomed Res Int       Date:  2016-05-30       Impact factor: 3.411

9.  In Vitro Activity of Oral Antimicrobial Agents against Pathogens Associated with Community-Acquired Upper Respiratory Tract and Urinary Tract Infections: A Five Country Surveillance Study.

Authors:  Douglas J Biedenbach; Robert E Badal; Ming-Yi Huang; Mary Motyl; Puneet K Singhal; Roman S Kozlov; Arthur Dessi Roman; Stephen Marcella
Journal:  Infect Dis Ther       Date:  2016-06-10

10.  Antimicrobial susceptibility and fluctuations in clonal complexes of serogroup 6 Streptococcus pneumoniae isolates collected from children in Beijing, China, between 1997 and 2016.

Authors:  Wei Shi; Ying Liu; Qinghong Meng; Lin Yuan; Wei Gao; Kaihu Yao
Journal:  Braz J Microbiol       Date:  2018-03-14       Impact factor: 2.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.